Avacta Group
plc
("Avacta"
or "the Group" or "the Company")
R&D Spotlight focusing on
pre|CISION®
technology and
pipeline advances
LONDON - Oct. 30, 2024 - Avacta
Therapeutics (AIM: AVCT), a life sciences company developing next
generation peptide drug conjugates (PDC) targeting powerful
antitumor payloads directly to the tumor, is today hosting a live
R&D Spotlight: "Next Generation of pre|CISION®
Medicines" in London.
Avacta's unique proprietary
technology allows for targeted delivery of cytotoxic drugs (the
"payload") in the tumor microenvironment (TME). The presentations
will cover the Company's next generation of follow-on candidates
with their unique features and patient populations.
Avacta will highlight in this event
the novel pre|CISION® candidates in the evolving
pipeline, details of which were presented at the EORTC-NCI-AACR
Triple Meeting in Barcelona last week and provide further detail on
their properties and patient populations.
Avacta's AVA6000, AVA6103, and
AVA7100 programs are highly differentiated pipeline assets,
addressing large markets. The presentation will also address these
programs' near-term milestones.
Avacta will highlight the franchise
it has developed in breast cancer and how these therapies in this
indication will move forward.
The Company confirms that the process
to divest the revenue-generating diagnostics division is ongoing
and it continues to actively explore opportunities for a potential
dual listing on NASDAQ. No additional financial information will be
disclosed.
This event is open to both analysts
and investors, further details are provided on the Company website
and a recording of the event will be made available in due
course.
For further information from Avacta
Group plc, please contact:
About the pre|CISION® Platform
The
pre|CISION® platform comprises an anticancer payload conjugated to a
proprietary peptide that is a highly specific substrate for
fibroblast activation protein (FAP) which is upregulated in most
solid tumors compared with healthy tissues. The
pre|CISION® platform harnesses this tumor specific protease to cleave
pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor
microenvironment, thus releasing active payload in the tumor and
reducing systemic exposure and toxicity, allowing dosing to be
optimized to deliver the best outcomes for patients.
About AVA6000: FAP-enabled doxorubicin
The lead
pre|CISION® program AVA6000, a peptide drug conjugate form of doxorubicin,
is in Phase 1 studies. It has shown an improvement in safety and
tolerability in clinical trials to date compared with standard
doxorubicin and preliminary signs of clinical activity in multiple
patients. To register for news alerts by email go
to https://avacta.com/investors/investor-news-email-alerts/.
AVA6103: FAP-enabled PDC targeting Topoisomerase
I
AVA6103 is a pre|CISION-enabled PDC
comprised of the pre|CISION peptide linked to exatecan, the most
potent topoisomerase I inhibitor in clinical development. Exatecan
has demonstrated clinical activity in breast, gastric, lung and
pancreatic cancers; however, it is associated with severe
dose-limiting toxicities and a short half-life in patients that led
to discontinuation of its monotherapy development. AVA6103 is
designed to enable patients to obtain the therapeutic benefit
associated with exatecan, while limiting the systemic exposure
associated with its poor tolerability.
AVA7100: pre|CISION® FAP Affimer Drug Conjugate (AffDC)
AVA7100 is a
pre|CISION®-enabled Affimer® drug
conjugate, a new class of therapies being developed by Avacta with
potential applications in a variety of cancer types, including
those with lower levels of FAP in the tumor.
Affimer® molecules are small proteins that are
engineered to bind to a target molecule in the same way that an
antibody does, but with several advantages, including smaller
molecule size and a broad range of binding affinity. AVA7100
consists of a novel FAP-Affimer conjugated to a
pre|CISION®-peptide linker with multiple options for the
payload.
About Avacta Group plc - https://avacta.com/
Avacta Group is a UK-based
life sciences company focused on improving healthcare outcomes
through targeted cancer treatments and diagnostics. Its clinical
stage oncology biotech division Avacta Therapeutics is harnessing
the proprietary pre|CISION® platform technology to develop
novel, highly targeted cancer drugs. Avacta
Diagnostics focuses on supporting healthcare professionals and
broadening access to diagnostics. To register for news alerts by
email go to https://avacta.com/investors/investor-news-email-alerts/.
